**Figure 1**




Figure 2




Figure 3




Figure 4




Figure 5

6/19




Figure 6




Figure 7




Figure 8

9/19




Figure 9

10/19




Figure 10

11/19





Figure 11

12/19

Enzymatic Therapeutics Inc. Attn. Ms Susan Blockington Accounts Payable 107 Diggers Drive East Berne, NY 12023 US	Invoice
Aarau, 11-Mar-2002 EMP	
INVOICE PAA-000002	
P.O.Number: email from Dr S. N. Maitland	
Project:	- / ENP03003
Product:	ENAA7856 HCl salt C-006012
Total:	2,691.99
Due	USD 2,691.99
Terms of payment:	30 days after receipt net
Payable to:	UBS AG, CH-9001 St. Gallen
	Account no. H0-276,389.2
	Clearing no. 123

Figure 12

Figure 13



Approach - Approach: AA-006012A-1-1-2-3-4-0003, ENP020021AABE-006012A-0011						
From		Created	To	In process	Project	Project
Overview		Categories	Objective	Conditions	Result	ENP02002
Approach	Approach	Project	Project	Chemist	Created D...	Status
AA-006012A-0001-0009		ENP02002.FRD.C-006012A-0001		MFA	30-Aug-2002	Created
AA-006012A-0003-0019		ENP02012.FRD.C-006012A-0003		MFA	19-Apr-2002	In process
AA-006012A-0003-0020		ENP02002.FRD.C-006012A-0003		MFA	24-Sep-2002	Print
AA-006012A-0004-0014		ENP02002.FRD.C-006012A-0004		MFA	12-Apr-2002	Archived
AA-006012A-0004-0015		ENP02002.FRD.C-006012A-0004		MFA	24-Sep-2002	Created
AA-006012A-1172/3-4-0002		ENP02002.LAB.C-006012A-0001		MFA	24-Sep-2002	Created
AA-006012A-1172/3-4-0003		ENP02002.LAB.C-006012A-0001		MFA	24-Sep-2002	Created
AA-006012A-1172/3-4-0002		ENP02002.LAB.C-006012A-0001		MFA	24-Sep-2002	Created
AA-006012A-1172/3L-0002		ENP02002.FRD.C-006012A-0003		MFA	24-Sep-2002	Created
AA-006012A-1172/3L-0003		ENP02002.FRD.C-006012A-0003		MFA	24-Sep-2002	Print
AA-006012A-1172/3L-0004		ENP02002.FRD.C-006012A-0003		MFA	24-Sep-2002	Created
AA-006012A-1172/3L-0005		ENP02002.FRD.C-006012A-0003		MFA	24-Sep-2002	Created
AA-006012A-1172/3L-0002		ENP02002.FRD.C-006012A-0003		MFA	24-Sep-2002	Created
AA-006012A-1172/3L-0003		ENP02002.FRD.C-006012A-0003		MFA	24-Sep-2002	Archived
AA-006012A-1172/3L-0004		ENP02002.FRD.C-006012A-0003		MFA	19-Apr-2002	Created
AA-006012A-1172/3L-0005		ENP02002.FRD.C-006012A-0003		MFA	30-Aug-2002	Created
AA-006012A-1172/3L-0001		ENP02002.FRD.C-006012A-0001		MFA		

Figure 14




Figure 15




Figure 16




Figure 17

Approach - Approach: AA-0000009-E-0001, ESK020-141012-010102-0011

From [Created] ▶ To [in process] ▶ Project []

Print ▶

Duplicate

X

	Overview	Categories	Objective	Conditions	Result
Yield	Purity	6.3 area %	75 %	Remarks	Complete conversion, ML contains 22 % product

Figure 18

19/19




Figure 19

Figure 20

CARBO GEN
Scilia Pharmaceutical Services Division

PP - Report

20-Mar-2003 / ADAFI

Page 1 of **

ENP02015 PRD.C-000009

Week:	12	Date:	20-Mar-2003
PTL:		Start date:	22-Aug-2002
PGL:		Planned end:	05-Nov-2002
Status:		End date:	22-Aug-2002

Experiment: AA-000009-E-0001-0001

Aim: Test Customer's procedure

Conditions: C-13332 (5 g) KOEt (1.1 eq), THF (50 mL), 0°C, 2 h
Work-up with EtOAc, NH4Cl, stripping to dryness, crystallization from 35 mL IPA at ambient temperature

Result:	Yield 75 %	Purity 6.3 area %	Remarks Complete conversion, ML contains 22 % product
---------	---------------	----------------------	---